Associated Papers
Genotype-Phenotype Correlation in Children With Cystic Fibrosis From India: A Multicentric Study.
Jat KR et al.
Clinical Genetics, 2026
Large variations in total and allele-specific transcript expression in a disease mutation-independent manner.
Freyberg M et al.
Scientific Reports, 2026
A therapeutic revolution: CFTR modulators in cystic fibrosis and their impacts on pregnant women and the fetus.
Denef M et al.
Journal of Perinatology : Official Journal of the California Perinatal Association, 2026
Therapeutic hopes for CFTR-related recurrent pancreatitis: a case-series.
Gohy S et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 2026
RFFL-mediated protein quality control limits functional rescue of TRID-CFTR modulator combination therapy for cystic fibrosis nonsense mutations.
Tateishi H et al.
Cellular and Molecular Life Sciences : Cmls, 2026
Translating Emerging Data for Fetal Treatment of Cystic Fibrosis.
Zaretsky MV et al.
Prenatal Diagnosis, 2026
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge.
Bassil CF et al.
Nature Communications, 2026
Barriers to the Pharmacologic Rescue of W1282X CFTR.
Manfredi C et al.
Biochemistry, 2026
Personalized Medicine in Cystic Fibrosis: Characterization of Eight Rare CFTR Variants in Intestinal Organoids and Cellular Models.
Railean V et al.
Molecular Diagnosis & Therapy, 2026
Genetic and clinical profile of neonates with meconium ileus: A case series.
Angadi C et al.
Tropical Doctor, 2026
Persistent plasma and RBC fatty acid abnormalities in children and adolescents with cystic fibrosis on highly effective CFTR modulators.
Yuzyuk T et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 2026
Advances in cystic fibrosis: CFTR modulator triple combinations.
Burgel PR et al.
The European Respiratory Journal, 2026
Strategies for the identification of people with cystic fibrosis responsive to CFTR modulator triple combinations.
Burgel PR
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 2026
Trikafta restores thermodynamic coupling between two nucleotide binding domains for potentiating CFTR activity.
Wang G
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2026
Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapies on Liver Transplant Outcomes.
Naimimohasses S et al.
Gastro Hep Advances, 2026
Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer.
Liu D et al.
Therapeutic Advances in Medical Oncology, 2026
Beyond the Surface: Novel Therapy Approach for Pancreatitis in the Setting of CFTR Dysfunction.
Wright BA et al.
Case Reports in Gastrointestinal Medicine, 2026
Whole-exome sequencing in children with dyslexia implicates rare variants in CLDN3 and ion channel genes.
Marianski K et al.
Human Genetics, 2025
LUNAR LNP delivery of CFTR mRNA restores channel function and improves mucociliary clearance in ferret cystic fibrosis airways.
Liu X et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy, 2025
Beyond the mutations: spatiotemporal regulation of CFTR by cAMP and calcium signaling in epithelial physiology and cystic fibrosis.
Varga A et al.
Cellular & Molecular Biology Letters, 2025
General trends in the calnexin-dependent expression and pharmacological rescue of clinical CFTR variants.
Tedman A et al.
Elife, 2025
Ligase-mediated programmable genomic integration (L-PGI).
Nan AX et al.
Nature Communications, 2025
Intrauterine Treatment in Two Fetuses Affected by Cystic Fibrosis: To Whom and Since When? Report of Cases.
Martínez Sánchez N et al.
Fetal Diagnosis and Therapy, 2025
Novel insight into CFTR gene's single nucleotide variants classification via in-silico analysis of a conserved site.
Rafique H et al.
Journal of Computer-aided Molecular Design, 2025
CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis.
Lo Cicero S et al.
Cells, 2025
Cystic fibrosis risk variants confer protection against inflammatory bowel disease.
Yu M et al.
Cell Genomics, 2025
Cystic fibrosis-related kidney disease-emerging morbidity and disease modifier.
Hart M et al.
Pediatric Nephrology (berlin, Germany), 2025
Beyond Carrier Status: CFTR Heterozygosity as an Overlooked Clinical Risk Factor for Pancreatitis.
Richter LD et al.
Clinical Genetics, 2025
Peptide CIGB-552 has a synergistic effect on CFTR-F508del when combined with elexacaftor/tezacaftor/ivacaftor triple therapy for cystic fibrosis.
Simonneau B et al.
British Journal of Pharmacology, 2025
Gene Editing for Cystic Fibrosis: Advances and Prospects of CRISPR-Cas9 Therapy.
Khurram I et al.
Cell Biology International, 2025
Next generation DNA sequencing data analysis and its application in clinical genomics.
Beura A et al.
Pathology, Research and Practice, 2025
Characterisation of pharmacogenomic variation in the Shetland and Orkney Isles in Scotland.
Twesigomwe D et al.
Scientific Reports, 2025
Molecular Prosthetics and CFTR Modulators Additively Increase Secretory HCO3- Flux in Cystic Fibrosis Airway Epithelia.
Celis N et al.
Acs Chemical Biology, 2025
In vivo conformational space and defects of misfolded CFTR variants by covalent protein painting.
Pankow S et al.
Nature Communications, 2025
CFTR correctors potentiate gating mutants causing cystic fibrosis.
Castanier S et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 2025
Effect of elexacaftor and bamocaftor on the metabolic and thermal stability of the F508del-CFTR protein in human airway epithelial cells.
Carrez T et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology, 2025
Cystic fibrosis as a paradigmatic disease in bringing science to the bedside.
Amaral MD et al.
Febs Letters, 2025
PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report.
Szentpetery S et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 2025
Successful Desensitisation With Cystic Fibrosis Transmembrane Conductance Regulator Modulatory Drugs in Delayed Cutaneous Hypersensitivity Reactions.
Kazancioglu A et al.
Journal of Paediatrics and Child Health, 2025
Efficacy of elexacaftor/tezacaftor/ivacaftor in non-cystic fibrosis bronchiectasis patients with a single pathogenic CFTR mutation: a retrospective cohort analysis.
Papadakis L et al.
Erj Open Research, 2025
When 25% Feels Like 100%: Confronting Recurrent Cystic Fibrosis Risk Across Consecutive Pregnancies.
Dasgupta S et al.
Cureus, 2025
Cystic Fibrosis and CFTR Modulators: The Impact on Bone Density, Muscle Mass and Strength in Children and Young Adolescents.
Iordanidou K et al.
Children (basel, Switzerland), 2025
Design and Characterization of 4D-710, an Aerosolized Gene Therapy for Cystic Fibrosis Lung Disease.
Calton MA et al.
American Journal of Respiratory Cell and Molecular Biology, 2025
A bibliometric analysis of cystic fibrosis transmembrane conductance regulators.
Araiqat B et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, 2025
Targeting the Aryl Hydrocarbon Receptor: The Potential of Indole Compounds in the Treatment of Cystic Fibrosis.
Hou S et al.
International Journal of Molecular Sciences, 2025
Generation of Region-specific Airway Basal Stem Cells from Human Pluripotent Stem Cells via Regulation of BMP-NOGGIN Axis.
Suzuki S et al.
Biorxiv : the Preprint Server for Biology, 2025